Evidence map›Paper›PMID 28096525›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2017

Toll-Like Receptor 4 Signaling in High Mobility Group Box-1 Protein 1 Mediated the Suppression of Regulatory T-Cells.

Chunyan Luo, Huiting Liu, Hu Wang, Jiajun Wang

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. AttenuatedFrontiers in immunology · 2026
    Review
  3. Review
  4. Article
  5. The Role of Complement Dysregulation in Glaucoma.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Article
  8. The Role of HMGB1 in Rheumatic Diseases.Frontiers in immunology · 2022
    Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Chunyan LuoSchool of Medical Science, Hubei University for Nationalities, Enshi, Hubei, China (mainland).
Huiting LiuDepartment of Nuclear Medicine, Chongqing Three Gorges Central Hospital, Wanzhou, Chongqing, China (mainland).
Hu WangMedical School, China Three Gorges University, Yichang, Hubei, China (mainland).
Jiajun WangSchool of Medical Science, Hubei University for Nationalities, Enshi, Hubei, China (mainland).
Hubei University for Nationalities · CNChina Three Gorges University · CNChongqing Three Gorges Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Treg cells play a central role in the suppression of immune response, and their suppressive capacity can be modulated by toll-like receptor (TLR) ligands. However, the detailed pathway of TLR ligand modulation is still unknown. The present study aimed to evaluate the effect of the high mobility group box-1 protein 1 (HMGB1) and lipopolysaccharide (LPS) on Treg cells through TLR4 signaling. MATERIAL AND METHODS Treg cells were purified from healthy human peripheral blood mononuclear cells (PBMCs) by magnetic-bead activity cell sorting (MACS), blocked by anti-TLR4 monoclonal antibody, and then incubated with different concentration of LPS or HMGB1. The level of gene expression of IL-1β, IL-10, IFN-γ, and TGF-β were detected using quantitative real-time polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA), and the proliferation of Treg cells after treating by LPS and HMGB1 was analyzed by flow cytometry. The NF-κB expression in Treg cells was examined by Western blotting. RESULTS LPS treated CD4 CD25 Treg cells directly increased the expression of IL-1b and IL-10 and decreased the expression of IFN-γ and TGF-β. However, HMGB1 treatment resulted in a marked decreased expression of IL-1β, IL-10, IFN-γ, and TGF-β. The proliferation of CD4+ T cells was significantly inhibited by Treg cells in the LPS treatment group, but weaken in the HMGB1 treatment group. These data suggest that HMGB1 and LPS stimulation could downregulate the expression NF-κB p65 in cytoplasmic proteins and increase the expression in nuclear proteins, thus leading to modulation of IL-1β, IL-10, IFN-γ, and TGF-β expression; moreover, the suppressive function of Treg cells could be regulated by TLR4. CONCLUSIONS TLR4 signaling in HMGB1 mediated the suppressive function of Treg cells through the activation of the NF-κB pathway.

Indexed as

Signal TransductionAntigens, CDCell ProliferationCytokinesFlow CytometryHMGB1 ProteinHumansLipopolysaccharidesNF-kappa BT-Lymphocytes, RegulatoryToll-Like Receptor 4Antigens, CDCytokinesHMGB1 ProteinLipopolysaccharidesNF-kappa BToll-Like Receptor 4

Identifiers

PMID28096525
PMCPMC5267620
OpenAlexW2578138872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.